Relmada Therapeutics

About Relmada Therapeutics

Relmada Therapeutics, Inc. is a clinical-stage biotechnology firm, founded in 2004, that has strategically pivoted its focus towards high-need therapeutic areas in oncology and central nervous system (CNS) disorders. The company is publicly traded on the NASDAQ exchange under the ticker RLMD. As a clinical-stage entity, Relmada does not currently generate revenue and operates by funding its research and development through capital raises. The company has communicated to investors that it has sufficient cash to fund operations into 2025 but will require additional financing to sustain its activities beyond that period.

The company's leadership is spearheaded by CEO Sergio Traversa, who brings over two decades of experience in the healthcare sector, including roles at Eli Lilly and Johnson & Johnson, as well as co-founding Medeor Inc., a pharmaceutical spin-off from Cornell University. His background spans management, strategic advisory, and investment within the pharmaceutical industry. The broader leadership team includes executives with extensive drug development experience from major biopharmaceutical companies.

Relmada's strategic focus shifted following the discontinuation of its former lead program, REL-1017 for major depressive disorder, in late 2024. The company now prioritizes the advancement of two key assets acquired to rebuild its pipeline. The lead investigational program is NDV-01, a sustained-release intravesical formulation of gemcitabine and docetaxel for non-muscle invasive bladder cancer (NMIBC). A Phase 2 study of NDV-01 showed a promising 91% overall response rate at a six-month follow-up, and the company is preparing for a Phase 3 registration trial scheduled to begin in the first half of 2026. This product targets a significant market, as NMIBC affects approximately 600,000 patients in the U.S. annually, and offers a potential non-surgical alternative.

The second key pipeline candidate is sepranolone, a first-in-class neurosteroid antagonist targeting disorders related to excessive GABAergic activity. This Phase 2b-ready program is being developed for compulsion-related disorders, with initial focus on Prader-Willi syndrome and Tourette's Syndrome. A Phase 2 study for sepranolone in patients with Prader-Willi syndrome is planned to commence in the first half of 2026. This program targets unmet needs in rare CNS disorders, potentially benefiting from orphan drug pathways.